Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Endoscopic management of familial colonic neoplasia.
   Gastrointest Endosc Clin N Am, 15(3): 549-80, ix-x. [Abstract] [Full-text]
2. Screening and surveillance of colorectal cancer.
   Gastrointest Endosc Clin N Am, 15(3): 533-47, ix. [Abstract] [Full-text]
3. Radiation exposure and familial aggregation of cancers as risk factors for colorectal cancer after radioiodine treatment for thyroid carcinoma.
   Int J Radiat Oncol Biol Phys, 62(4): 1084-9. [Abstract] [Full-text]
4. The properties of the mitochondrial megachannel in mitoplasts from human colon carcinoma cells are not influenced by Bax.
   FEBS Lett, 579(17): 3695-700. [Abstract] [Full-text]
5. Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
   FEBS Lett, 579(17): 3497-502. [Abstract] [Full-text]
6. Tribromomethane exposure and dietary folate deficiency in the formation of aberrant crypt foci in the colons of F344/N rats.
   Food Chem Toxicol, 43(9): 1405-12. [Abstract] [Full-text]
7. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.
   Cancer Res, 65(13): 5935-44. [Abstract] [Full-text]
8. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
   Cancer Res, 65(13): 5917-24. [Abstract] [Full-text]
9. Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system.
   Cancer Res, 65(13): 5872-80. [Abstract] [Full-text]
10. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
    Cancer Res, 65(13): 5864-71. [Abstract] [Full-text]
11. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
    Cancer Res, 65(13): 5848-56. [Abstract] [Full-text]
12. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity.
    Cancer Res, 65(13): 5812-7. [Abstract] [Full-text]
13. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers.
    Cancer Res, 65(13): 5740-9. [Abstract] [Full-text]
14. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.
    Cancer Res, 65(13): 5498-505. [Abstract] [Full-text]
15. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer.
    Cancer Res, 65(13): 5488-92. [Abstract] [Full-text]
16. Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network.
    J Clin Oncol, 23(19): 4414-23. [Abstract] [Full-text]
17. Chromosome alterations in colorectal cancer in Thai patients.
    Cancer Genet Cytogenet, 160(2): 152-9. [Abstract] [Full-text]
18. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial.
    Lancet Oncol, 6(7): 477-84. [Abstract] [Full-text]
19. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
    Lancet Oncol, 6(7): 459-68. [Abstract] [Full-text]
20. Upregulation of MUC6 mucin gene expression by NFkappaB and Sp factors.
    Biochem Biophys Res Commun, 333(4): 1254-60. [Abstract] [Full-text]
21. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer.
    Dis Colon Rectum, 48(7): 1343-9; discussion 1349-52; author reply 1352. [Abstract] [Full-text]
22. Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801).
    Dis Colon Rectum, 48(7): 1389-96. [Abstract] [Full-text]
23. Transanal excision vs. major surgery for T1 rectal cancer.
    Dis Colon Rectum, 48(7): 1380-8. [Abstract] [Full-text]
24. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer.
    Dis Colon Rectum, 48(7): 1353-65. [Abstract] [Full-text]
25. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
    J Cell Physiol, 204(3): 742-9. [Abstract] [Full-text]
26. Clinical and molecular characteristics of hereditary non-polyposis colorectal cancer families in Southeast Asia.
    Clin Genet, 68(2): 137-45. [Abstract] [Full-text]
27. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis.
    Proteomics, 5(10): 2602-11. [Abstract] [Full-text]
28. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer.
    Proteomics, 5(10): 2587-601. [Abstract] [Full-text]
29. Adenocarcinoma of the rectum in childhood following chemotherapy and radiotherapy for a rhabdomyosarcoma--a case report.
    Eur J Pediatr Surg, 15(3): 210-2. [Abstract] [Full-text]
30. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial.
    J Natl Cancer Inst, 97(13): 989-97. [Abstract] [Full-text]
31. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
    J Natl Cancer Inst, 97(13): 981-9. [Abstract] [Full-text]
32. Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon.
    Pathol Int, 55(8): 524-9. [Abstract] [Full-text]
33. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma.
    Br J Cancer, 93(1): 131-6. [Abstract] [Full-text]
34. Role of netrin-1 and netrin-1 dependence receptors in colorectal cancers.
    Br J Cancer, 93(1): 1-6. [Abstract] [Full-text]
35. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma.
    Cancer, 104(2): 395-404. [Abstract] [Full-text]
36. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma.
    Cancer, 104(2): 273-81. [Abstract] [Full-text]
37. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Cancer, 104(2): 282-9. [Abstract] [Full-text]
38. Exposure to the electrofusion process can increase the immunogenicity of human cells.
    Cancer Immunol Immunother, 54(9): 880-90. [Abstract] [Full-text]
39. Furanoid sugar amino acids as dipeptide mimics in design of analogs of vasoactive intestinal peptide receptor binding inhibitor.
    J Pept Res, 66(2): 75-84. [Abstract] [Full-text]
40. Systemic therapy for metastatic colorectal cancer: current options, current evidence.
    J Clin Oncol, 23(20): 4553-60. [Abstract] [Full-text]
41. Role of genomic markers in colorectal cancer treatment.
    J Clin Oncol, 23(20): 4545-52. [Abstract] [Full-text]
42. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results.
    J Vasc Interv Radiol, 16(7): 937-45. [Abstract] [Full-text]
43. Inguinal canal as an anatomic sanctuary site of relapse in peritoneal carcinomatosis previously treated with intraperitoneal chemotherapy.
    J Surg Oncol, 91(1): 73-6. [Abstract] [Full-text]
44. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer.
    J Clin Invest, 115(7): 1765-76. [Abstract] [Full-text]
45. Targeted therapy for colorectal cancer: mapping the way.
    Trends Mol Med, 11(7): 327-35. [Abstract] [Full-text]
46. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer.
    J Biol Chem, 280(28): 26565-72. [Abstract] [Full-text]
47. The validity of the family relationships index as a screening tool for psychological risk in families of cancer patients.
    Psychooncology, 14(7): 546-54. [Abstract] [Full-text]
48. Glutathione S-transferases activity in patients with colorectal cancer.
    Clin Biochem, 38(7): 621-4. [Abstract] [Full-text]
49. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc(Min/+) mice.
    Gut, 54(8): 1136-45. [Abstract] [Full-text]
50. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
    Endocrinology, 146(8): 3235-43. [Abstract] [Full-text]
51. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma.
    Gut, 54(8): 1146-50. [Abstract] [Full-text]
52. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.
    Gut, 54(8): 1129-35. [Abstract] [Full-text]
53. CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
    Cancer Immunol Immunother, 54(8): 750-8. [Abstract] [Full-text]
54. Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.
    Cancer Immunol Immunother, 54(8): 781-91. [Abstract] [Full-text]
55. Histamine receptor antagonists and incident colorectal adenomas.
    Aliment Pharmacol Ther, 22(2): 123-8. [Abstract] [Full-text]
56. Isolated crypts form spheres prior to full intestinal differentiation when grown as xenografts: an in vivo model for the study of intestinal differentiation and crypt neogenesis, and for the abnormal crypt architecture of juvenile polyposis coli.
    J Pathol, 206(4): 395-401. [Abstract] [Full-text]
57. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.
    Biochem Pharmacol, 70(4): 580-9. [Abstract] [Full-text]
58. Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways.
    Food Chem Toxicol, 43(10): 1483-95. [Abstract] [Full-text]
59. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers.
    Cancer Res, 65(14): 6418-24. [Abstract] [Full-text]
60. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells.
    Cancer Res, 65(14): 6380-7. [Abstract] [Full-text]
61. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program.
    Cancer Res, 65(14): 6237-44. [Abstract] [Full-text]
62. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
    Cancer Res, 65(14): 6151-8. [Abstract] [Full-text]
63. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.
    Cancer Res, 65(14): 6063-9. [Abstract] [Full-text]
64. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer.
    Cancer Res, 65(14): 6017-21. [Abstract] [Full-text]
65. Pre-operative imaging of rectal cancer and its impact on surgical performance and treatment outcome.
    Eur J Surg Oncol, 31(6): 681-8. [Abstract] [Full-text]
66. Education is the key to quality of surgery for rectal cancer.
    Eur J Surg Oncol, 31(6): 636-44. [Abstract] [Full-text]
67. Numerical and structural centrosome aberrations are an early and stable event in the adenoma-carcinoma sequence of colorectal carcinomas.
    Virchows Arch, 447(1): 61-5. [Abstract] [Full-text]
68. Quality control issues in the management of colon cancer patients.
    Eur J Surg Oncol, 31(6): 616-29. [Abstract] [Full-text]
69. Pathological quality assurance in gastro-intestinal cancer.
    Eur J Surg Oncol, 31(6): 675-80. [Abstract] [Full-text]
70. The influence on treatment outcome of structuring rectal cancer care.
    Eur J Surg Oncol, 31(6): 645-9. [Abstract] [Full-text]
71. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins.
    Mol Pharmacol, 68(2): 317-29. [Abstract] [Full-text]
72. Surgical quality assurance in rectal cancer treatment: the key to improved outcome.
    Eur J Surg Oncol, 31(6): 630-5. [Abstract] [Full-text]
73. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice.
    Int J Cancer, 116(4): 495-9. [Abstract] [Full-text]
74. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
    Cancer Gene Ther, 12(8): 673-81. [Abstract] [Full-text]
75. Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study.
    Arch Surg, 140(7): 692-7. [Abstract] [Full-text]
76. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
    Eur J Cancer, 41(11): 1551-9. [Abstract] [Full-text]
77. The prevalence of PIK3CA mutations in gastric and colon cancer.
    Eur J Cancer, 41(11): 1649-54. [Abstract] [Full-text]
78. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
    Eur J Cancer, 41(11): 1542-6. [Abstract] [Full-text]
79. Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells.
    Eur J Cancer, 41(11): 1618-27. [Abstract] [Full-text]
80. Reorganization of ErbB family and cell survival signaling after Knock-down of ErbB2 in colon cancer cells.
    J Biol Chem, 280(29): 27383-92. [Abstract] [Full-text]
81. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1823-7. [Abstract] [Full-text]
82. Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1819-22. [Abstract] [Full-text]
83. Spectral markers in preneoplastic intestinal mucosa: an accurate predictor of tumor risk in the MIN mouse.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1639-45. [Abstract] [Full-text]
84. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1633-8. [Abstract] [Full-text]
85. Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1626-32. [Abstract] [Full-text]
86. Fruits, vegetables, and hMLH1 protein-deficient and -proficient colon cancer: The Netherlands cohort study.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1619-25. [Abstract] [Full-text]
87. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1613-8. [Abstract] [Full-text]
88. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1608-12. [Abstract] [Full-text]
89. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
    Int J Radiat Oncol Biol Phys, 62(5): 1363-70. [Abstract] [Full-text]
90. HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
    Dis Colon Rectum, 48(8): 1656-9. [Abstract] [Full-text]
91. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer.
    J Clin Oncol, 23(21): 4705-12. [Abstract] [Full-text]
92. Four-color staining combining fluorescence and brightfield microscopy for simultaneous immune cell phenotyping and localization in tumor tissue sections.
    Microsc Res Tech, 67(1): 15-21. [Abstract] [Full-text]
93. Retrorectal tumors: a diagnostic and therapeutic challenge.
    Dis Colon Rectum, 48(8): 1581-7. [Abstract] [Full-text]
94. Accuracy of magnetic resonance imaging in rectal cancer depends on location of the tumor.
    Dis Colon Rectum, 48(8): 1603-9. [Abstract] [Full-text]
95. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.
    Dis Colon Rectum, 48(8): 1597-602. [Abstract] [Full-text]
96. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis.
    Dis Colon Rectum, 48(8): 1588-96. [Abstract] [Full-text]
97. The effect of preoperative radiotherapy on systemic collagen deposition and postoperative infective complications in rectal cancer patients.
    Dis Colon Rectum, 48(8): 1573-80. [Abstract] [Full-text]
98. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease.
    Dis Colon Rectum, 48(8): 1528-34. [Abstract] [Full-text]
99. Novel therapeutics in colorectal cancer.
    Dis Colon Rectum, 48(8): 1632-50. [Abstract] [Full-text]
100. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?
     J Clin Oncol, 23(21): 4609-16. [Abstract] [Full-text]
101. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin).
     Carcinogenesis, 26(8): 1450-6. [Abstract] [Full-text]
102. Associations between apoE genotype and colon and rectal cancer.
     Carcinogenesis, 26(8): 1422-9. [Abstract] [Full-text]
103. Loss of mismatch repair protein immunostaining in colorectal adenomas from patients with hereditary nonpolyposis colorectal cancer.
     Mod Pathol, 18(8): 1095-101. [Abstract] [Full-text]
104. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.
     Cancer Lett, 226(2): 115-21. [Abstract] [Full-text]
105. Radiological appearances in the pelvis following rectal cancer surgery.
     Clin Radiol, 60(8): 846-55. [Abstract] [Full-text]
106. Number versus distribution in classifying regional lymph node metastases from colon cancer.
     J Am Coll Surg, 201(2): 217-22. [Abstract] [Full-text]
107. Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
     J Surg Oncol, 91(2): 134-40. [Abstract] [Full-text]
108. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
     J Surg Oncol, 91(2): 97-101. [Abstract] [Full-text]
109. Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.
     Mol Carcinog, 43(4): 207-14. [Abstract] [Full-text]
110. Differences in colorectal carcinoma stage and survival by race and ethnicity.
     Cancer, 104(3): 629-39. [Abstract] [Full-text]
111. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues.
     J Biol Chem, 280(30): 27826-31. [Abstract] [Full-text]
112. Plasma carotenoid, alpha-tocopherol and retinol concentrations and risk of colorectal adenomas: A case-control study in Japan.
     Cancer Lett, 226(2): 133-41. [Abstract] [Full-text]
113. Quality of life in colorectal cancer patients with colectomy and the validation of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), Version 4.
     J Pain Symptom Manage, 30(1): 24-32. [Abstract] [Full-text]
114. Association of hereditary hemorrhagic telangiectasia and hereditary nonpolyposis colorectal cancer in the same kindred.
     Int J Cancer, 116(5): 808-12. [Abstract] [Full-text]
115. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer.
     Int J Cancer, 116(5): 692-702. [Abstract] [Full-text]
116. Cancer incidence among Danish brewery workers.
     Int J Cancer, 116(5): 774-8. [Abstract] [Full-text]
117. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors.
     Int J Cancer, 116(5): 762-7. [Abstract] [Full-text]
118. Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7.
     Int J Cancer, 116(5): 726-33. [Abstract] [Full-text]
119. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
     Histopathology, 47(2): 141-6. [Abstract] [Full-text]
120. Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture.
     Int J Exp Pathol, 86(4): 219-29. [Abstract] [Full-text]
121. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
     Cancer Chemother Pharmacol, 56(4): 421-6. [Abstract] [Full-text]
122. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
     Cancer Chemother Pharmacol, 56(4): 379-90. [Abstract] [Full-text]
123. Discordant quantitative detection of putative biomarkers in nodal micrometastases of colorectal cancer: biological and clinical implications.
     J Clin Pathol, 58(8): 839-44. [Abstract] [Full-text]
124. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.
     J Clin Pathol, 58(8): 833-8. [Abstract] [Full-text]
125. Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.
     J Clin Pathol, 58(8): 811-4. [Abstract] [Full-text]
126. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?
     J Clin Oncol, 23(22): 4905-12. [Abstract] [Full-text]
127. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
     J Clin Oncol, 23(22): 4881-7. [Abstract] [Full-text]
128. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
     J Clin Oncol, 23(22): 4888-96. [Abstract] [Full-text]
129. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
     J Clin Oncol, 23(22): 4856-65. [Abstract] [Full-text]
130. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
     J Clin Oncol, 23(22): 4866-75. [Abstract] [Full-text]

© 2004-2008 Colorectal Cancer Research Today. All Rights Reserved.